Research Peptide
Buy Tirzepatide For Research: The Dual GIP/GLP-1 Peptide, Trials, and COA
Updated · 4 cited sources · ResearchChem Research Team
Short answer: ResearchChem supplies tirzepatide as a research-use vial at 40 mg for $120, with every lot shipped with a lot number and a Certificate of Analysis sent on request. Tirzepatide (Lilly code LY3298176) is a 39-amino-acid synthetic peptide that behaves as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The research literature studies it as a dual-incretin agonist, separate from the FDA-approved products (Mounjaro, Zepbound) that Eli Lilly markets for specific human indications. The research vial is supplied for in-vitro and animal research only.
The tirzepatide research vial, exactly as shipped
- SKU: TIRZ-40. Size: 40 mg lyophilized peptide in one vial.
- Price: $120 (/shop/tirzepatide).
- Shipping: US domestic, cold-chain insulated — no customs hold.
- Compliance line on the 40×20 mm label: "RESEARCH USE ONLY · NOT FOR HUMAN USE".
- COA: the lot-specific Certificate of Analysis is sent on request — email [email protected] with the lot number from the vial.
- Storage: unopened at −20 °C; reconstitute with bacteriostatic water for in-vitro use.
Every order of $50 or more also receives one 100 mg GHK-Cu research vial free (SKU GHKCU-100); see free GHK-Cu with any $50 order for the exact offer terms.
What tirzepatide is as a compound
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The Coskun 2018 discovery paper (Molecular Metabolism) describes it as a fatty-acid-modified peptide designed for a long serum half-life, suitable for a weekly research protocol. The modification is a C20 fatty-diacid moiety on the lysine at position 20, which binds endogenous serum albumin and slows enzymatic clearance [1]. In preclinical work the paper reports potent GIP and GLP-1 receptor activation in cell assays, and in a phase 1 human study it produced dose-dependent HbA1c reduction in people with type 2 diabetes.
Tirzepatide is not a pure GLP-1 analog. The mechanism primer at semaglutide vs tirzepatide mechanism covers the dual-agonism argument and how GIP + GLP-1 together differ from a single-receptor agonist.
What peer-reviewed trials have reported
The SURPASS-1 trial (Rosenstock and colleagues, Lancet 2021) was a 40-week monotherapy study of tirzepatide vs placebo in 478 adults with type 2 diabetes inadequately controlled by diet and exercise. All three tirzepatide groups produced a reduction in HbA1c versus placebo (P < 0.0001 for every comparison), with mean HbA1c reductions in the −1.87% to −2.07% range from a baseline near 7.9% [2]. The drug was the first dual GIP and GLP-1 receptor agonist evaluated in a monotherapy Phase 3 trial.
The SURPASS-2 trial (Frías and colleagues, NEJM 2021) was the head-to-head comparison against semaglutide 1 mg weekly in 1,879 adults with type 2 diabetes. Across the three tirzepatide groups, mean HbA1c reduction was −2.01%, −2.24%, and −2.30% from a baseline of 8.28%, versus −1.86% for semaglutide — every tirzepatide group was non-inferior and superior to semaglutide (P < 0.001 for all three comparisons) [3].
The SURMOUNT-1 obesity trial (Jastreboff and colleagues, NEJM 2022) randomized 2,539 adults with obesity (BMI ≥ 30, or ≥ 27 with one weight-related comorbidity) and no diabetes to 72 weeks of tirzepatide or placebo. Mean percent change in body weight was −15.0%, −19.5%, and −20.9% across the three tirzepatide groups, versus −3.1% for placebo (P < 0.001 for every comparison) [4]. The most common adverse events were gastrointestinal (nausea, diarrhea, constipation), mostly mild to moderate and dose-dependent.
The numbers above are measurements from the cited peer-reviewed trials. The ResearchChem vial is supplied for in-vitro and animal research only; the paragraphs are not instructions for use.
What the COA on a tirzepatide lot shows
| Field | What it tells you | What to check |
|---|---|---|
| Lot number | Which production run the results belong to | Matches the lot printed on the vial |
| Sequence or formula | Which molecule was tested | The 39-residue tirzepatide sequence with the C20 fatty-diacid-modified Lys20; empirical formula near C225H348N48O68 |
| Identity (MS) | Measured molecular mass vs theoretical mass | Observed monoisotopic mass matches the published 4,813.5 Da theoretical value |
| Purity (HPLC) | Share of UV-absorbing material that is the main peak | A percentage value plus the chromatogram; related-substances table identifying any secondary peaks |
| Methods and limits | How each result was produced and what counts as a pass | Acceptance criteria next to every result |
| Lab, date, sign-off | Who tested it and when | Lab name, analysis date, analyst or QA signature |
See how to read a peptide COA for a field-by-field walkthrough. The purity figure is covered in more detail in HPLC peptide purity explained.
Regulatory status of tirzepatide the drug
Tirzepatide is the active ingredient of two FDA-approved Eli Lilly products: Mounjaro, approved in May 2022 for type 2 diabetes, and Zepbound, approved in November 2023 for chronic weight management. Both are prescription drugs dispensed through pharmacies on the authority of a prescribing clinician. The ResearchChem research vial is a separate supply: labelled research use only, shipped without a prescription, and intended for in-vitro and animal research. The research vial is not interchangeable with Mounjaro or Zepbound and is not supplied for human use.
US-domestic sourcing
For US-based research use, a supplier should ship from within the US, supply a lot-specific COA on request, and label every vial with the standard RUO compliance line. ResearchChem carries the research vial at /shop/tirzepatide for $120 (40 mg), shipped cold-chain.
Frequently asked questions
Can I buy tirzepatide for research use in the US?
Yes. ResearchChem supplies the research vial at /shop/tirzepatide (40 mg, $120), shipped from within the US. Every vial carries the RUO compliance line and the lot-specific COA is sent on request.
What is tirzepatide as a compound?
A 39-amino-acid synthetic peptide engineered as a dual agonist of the GIP and GLP-1 receptors. It has a C20 fatty-diacid modification on Lys20 that slows clearance by binding endogenous serum albumin.
Is tirzepatide an approved drug?
Yes, as two FDA-approved Eli Lilly products — Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). Both are prescription drugs dispensed through pharmacies. The ResearchChem research vial is a separate supply, labelled research use only and shipped without a prescription for in-vitro and animal research.
How is tirzepatide different from semaglutide?
Semaglutide is a single-receptor agonist (GLP-1 only). Tirzepatide activates both GLP-1 and GIP receptors. In the head-to-head SURPASS-2 trial, every tirzepatide group was non-inferior and superior to semaglutide 1 mg weekly on HbA1c reduction in people with type 2 diabetes.
What papers document tirzepatide?
Coskun 2018 (Mol Metab) characterized the discovery and phase 1 data. The SURPASS program (Rosenstock 2021 Lancet; Frías 2021 NEJM) reported the type 2 diabetes trials. SURMOUNT-1 (Jastreboff 2022 NEJM) reported the obesity trial that preceded the Zepbound approval.
Does the COA cover the whole lot?
Yes. The lot-specific COA is generated once per production run and applies to every vial that carries that lot number.
Cited studies
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.. Mol Metab. 18:3-14 (2018). PubMed 30473097 DOI
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. Lancet. 398(10295):143-155 (2021). PubMed 34186022 DOI
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. N Engl J Med. 385(6):503-515 (2021). PubMed 34170647 DOI
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity.. N Engl J Med. 387(3):205-216 (2022). PubMed 35658024 DOI
Related compounds
- Tirzepatide — Dual-Agonist Peptide
Keep reading
Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.